IBRUTINIB
Information current as at: 1 April 2026
The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.
Submission Details
- Brand name:
-
- Imbruvica®
- Form and strength:
- Please search for and view the medicine's Public Summary Document (PSD) for more information
- Condition/indication:
(therapeutic use) -
- Chronic lymphocytic leukaemia (CLL); small lymphocytic lymphoma (SLL)
- Listing requested:
- Please see PSD for more information
- Funding program:
- Please see PSD for more information
- Request authority level:
- Please see PSD for more information
- PBAC submission type:
- Change to listing (Major)
- Comment:
- --
- Submission sponsor:
- Janssen-Cilag Pty Ltd
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - November 2019 PBAC meeting
-
Opportunity for consumer comment: - Open 28/08/2019 and close 09/10/2019 (see PBS Website)
-
PBAC meeting: - Held on 06/11/2019
-
4PBAC outcome published:
- Recommended (see PBAC Outcomes)
-
Notice of intent submitted:
- Awaiting lodgement from pharmaceutical company
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
PBAC Outcome
Case ID: a075
Page last updated: 31 March 2026